The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
HYPOGONADISM AND METABOLIC SYNDROME: IMPLICATIONS FOR TESTOSTERONE THERAPY
Abstract
PURPOSE: Metabolic syndrome, characterized by central obesity, insulin resistance, dyslipidemia and hypertension, is highly prevalent in the United States. When left untreated, it significantly increases the risk of diabetes mellitus and cardiovascular disease. It has been suggested that hypogonadism may be an additional component of metabolic syndrome. This has potential implications for the treatment of metabolic syndrome with testosterone. We reviewed the available literature on metabolic syndrome and hypogonadism with a particular focus on testosterone therapy. MATERIALS AND METHODS: A comprehensive MEDLINE review of the world literature from 1988 to 2004 on hypogonadism, testosterone and metabolic syndrome was performed. RESULTS: Observational data suggest that metabolic syndrome is strongly associated with hypogonadism in men. Multiple interventional studies have shown that exogenous testosterone has a favorable impact on body mass, insulin secretion and sensitivity, lipid profile and blood pressure, which are the parameters most often disturbed in metabolic syndrome. CONCLUSIONS: Hypogonadism is likely a fundamental component of metabolic syndrome. Testosterone therapy may not only treat hypogonadism, but may also have tremendous potential to slow or halt the progression from metabolic syndrome to overt diabetes or cardiovascular disease via beneficial effects on insulin regulation, lipid profile and blood pressure. Furthermore, the use of testosterone to treat metabolic syndrome may also lead to the prevention of urological complications commonly associated with these chronic disease states, such as neurogenic bladder and erectile dysfunction. Physicians must be mindful to evaluate hypogonadism in all men diagnosed with metabolic syndrome as well as metabolic syndrome in all men diagnosed with hypogonadism. Future research in the form of randomized clinical trials should focus on further defining the role of testosterone for metabolic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssönen, K., Tuomainen, T.-P., Valkonen, V.-P., Salonen, R., & Salonen, J. T. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1036 · Cited by 920
Effect of Lifestyle Changes on Erectile Dysfunction in Obese Men: A Randomized Controlled Trial
Esposito, K., Giugliano, F., Di Palo, C., Giugliano, G., Marfella, R., D'Andrea, F., D'Armiento, M., & Giugliano, D. (2004) · JAMA · doi:10.1001/jama.291.24.2978 · Cited by 841
Katznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954042 · Cited by 791
PLYMATE, S. R., MATEJ, L. A., JONES, R. E., & FRIEDL, K. E. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-3-460 · Cited by 693
English, K. M., Steeds, R. P., Jones, T. H., Diver, M. J., & Channer, K. S. (2000) · Circulation · doi:10.1161/01.cir.102.16.1906 · Cited by 582
Seidell, J. C., Björntorp, P., Sjöström, L., Kvist, H., & Sannerstedt, R. (1990) · Metabolism · doi:10.1016/0026-0495(90)90297-p · Cited by 567
Effects of Testosterone on Coronary Vasomotor Regulation in Men With Coronary Heart Disease
Webb, C. M., McNeill, J. G., Hayward, C. S., de Zeigler, D., & Collins, P. (1999) · Circulation · doi:10.1161/01.cir.100.16.1690 · Cited by 451
Sex hormones, inflammation and the metabolic syndrome: a population-based study
Laaksonen, D., Niskanen, L., Punnonen, K., Nyyssonen, K., Tuomainen, T., Salonen, R., Rauramaa, R., & Salonen, J. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1490601 · Cited by 438
Insulin resistance as the core defect in type 2 diabetes mellitus
Goldstein, B. J. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02553-5 · Cited by 432
Boyanov, M. A., Boneva, Z., & Christov, V. G. (2003) · The Aging Male · doi:10.1080/tam.6.1.1.7 · Cited by 381
Cited by
Lifestyle factors and reproductive health: taking control of your fertility
Sharma, R., Biedenharn, K. R., Fedor, J. M., & Agarwal, A. (2013) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-11-66 · Cited by 845
Low Serum Testosterone and Mortality in Older Men
Laughlin, G. A., Barrett-Connor, E., & Bergstrom, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1792 · Cited by 798
Testosterone: a metabolic hormone in health and disease
Kelly, D. M., & Jones, T. H. (2013) · Journal of Endocrinology · doi:10.1530/joe-12-0455 · Cited by 577
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
Zhu, M.-L., Horbinski, C. M., Garzotto, M., Qian, D. Z., Beer, T. M., & Kyprianou, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0585 · Cited by 352
Meacham, L. R., Sklar, C. A., Li, S., Liu, Q., Gimpel, N., Yasui, Y., Whitton, J. A., Stovall, M., Robison, L. L., & Oeffinger, K. C. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.209 · Cited by 339
Metadata
- Authors
- MAKHSIDA, N., SHAH, J., YAN, G., FISCH, H., & SHABSIGH, R.
- Venue
- Journal of Urology
- Published
- 2005-09
- Volume
- 174
- Issue
- 3
- Pages
- 827-834
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2122895485
- Cited by
- 229
- References
- 12
- FWCI
- 13.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HYPOGONADISM AND METABOLIC SYNDROME: IMPLICATIONS FOR TESTOSTERONE THERAPY. https://app.cochat.ai/papers/10.1097/01.ju.0000169490.78443.59
- The paper
- MAKHSIDA, N., SHAH, J., YAN, G., FISCH, H., & SHABSIGH, R. (2005). HYPOGONADISM AND METABOLIC SYNDROME: IMPLICATIONS FOR TESTOSTERONE THERAPY. Journal of Urology. https://doi.org/10.1097/01.ju.0000169490.78443.59
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.